Li Ka Shing This from the 1st Quarter news letter April 2021
well worth remembering especially when when the stock has no respect from investors. This should be a game changer for Theralase, and bring us some respect and investor awareness I hope. Also Li KaShing could help finance our GBM and Lung Trials maybe as a partner who knows, but I bought more stock today, my 75k share bid at .20 got filled, or almost filled, left me standing on the bid for 2500 more.
All in my opinion which is pretty optimistic even though the price of the stock is an imbarasment for now!
cashascars
In April 2021, the Company launched the Theralase® Anti-Cancer Therapy (“ACT”) research center located within the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Unity Health Toronto, relocating its research team from University Health Network (“UHN”).
The ACT research center is a fully equipped laboratory dedicated exclusively to Theralase® ACT research and development, as Theralase® advances towards commercialization with its lead PDC, TLD-1433, as well as its systemic and targeted formulation – Rutherrin®. A partnership with the Li Ka Shing Knowledge Institute of Unity Health provides access to additional expertise, advisory networks and opportunities to accelerate product development and commercialization.